GlassScriptPhysician profile
Jane Clarissa Powell
NPI 1548784986
$6,628.28
in general payments reported to CMS, 2019-2025
22 companies · $1,128 in 2025
The $1,128 reported for 2025 was more than what 83% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $564 · 2022: $728 · 2023: $994 · 2024: $3,215 · 2025: $1,128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,929 · Travel and Lodging: $1,296 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,928.75 |
| Travel and Lodging | $1,295.84 |
| Education | $111.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $2,074.68 | 2024-2025 | Cobenfy |
| Abbvie INC. | $1,422.52 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $722.49 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $548.37 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lundbeck LLC | $378.27 | 2021-2025 | Rexulti |
| Alkermes, INC. | $335.38 | 2021-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $266.09 | 2021-2025 | Invega Sustenna, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $206.89 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $171.01 | 2021-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $93.56 | 2022-2024 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $77.32 | 2023-2025 | Qelbree, Qelbree |
| Almatica Pharma LLC | $73.27 | 2021-2023 | Loreev Xr, Sertraline Hcl |
| Idorsia Pharmaceuticals US INC | $67.43 | 2023-2024 | Quviviq |
| Axsome Therapeutics, INC. | $36.28 | 2023-2025 | Auvelity |
| Eisai INC. | $24.45 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $22.34 | 2021 | |
| Glaxosmithkline, LLC. | $19.71 | 2021 | |
| Corium, LLC | $19.16 | 2023 | Azstarys |
| Harmony Biosciences LLC | $18.04 | 2024 | |
| Lilly USA, LLC | $17.89 | 2021 | |
| Vanda Pharmaceuticals INC. | $17.56 | 2025 | Fanapt |
| Jazz Pharmaceuticals INC. | $15.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.